Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inflammatory bowel disease07.08.01.0160.000606%Not Available
Influenza like illness08.01.03.0100.001849%
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.001334%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.001849%Not Available
Injection site pruritus12.07.03.014; 08.02.03.013; 23.03.12.0070.000818%Not Available
Injection site vesicles23.03.01.024; 12.07.03.051; 08.02.03.0510.000667%Not Available
Injury corneal12.01.04.018; 06.11.03.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.002728%Not Available
Intestinal stenosis07.13.01.0030.000303%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.001121%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint contracture15.01.08.0010.001030%Not Available
Joint stiffness15.01.02.0030.001697%Not Available
Joint swelling15.01.02.0040.005789%Not Available
Kawasaki's disease24.12.02.004; 11.07.01.007; 10.02.02.009--Not Available
Laryngotracheal oedema23.04.01.011; 22.04.02.005; 10.01.05.011--Not Available
Leukocytosis01.02.01.0020.000909%
Leukopenia01.02.02.0010.002728%Not Available
Lichen planus23.03.08.001--Not Available
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.0040.000303%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.002243%Not Available
Liver disorder09.01.08.0010.001212%Not Available
Liver function test abnormal13.03.04.030--Not Available
Liver transplant25.09.02.001--Not Available
Lung disorder22.02.07.0010.001667%Not Available
Lung infiltration22.01.02.0040.000303%Not Available
Lymphadenitis01.09.01.0010.000303%Not Available
Lymphadenopathy01.09.01.0020.002425%Not Available
Lymphocytosis01.02.01.0030.000455%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene